Antibody profile in Indian severe haemophilia A patients with and without FVIII inhibitors

被引:1
|
作者
Pinto, Patricia [1 ]
Shetty, Shrimati [1 ]
Lacroix-Desmazes, Sebastien [2 ,3 ,4 ,5 ,6 ]
Bayry, Jagadeesh [2 ,3 ,4 ,5 ,6 ]
Kaveri, Srini [2 ,3 ,4 ,5 ,6 ]
Ghosh, Kanjaksha [1 ]
机构
[1] Natl Inst Immunohaematol ICMR, 13th Floor,New Multistoreyed Bldg,KEM Hosp Campus, Bombay 400012, Maharashtra, India
[2] Ctr Rech Cordeliers, INSERM, UMRS 1138, Paris, France
[3] Univ Paris 06, UMRS 1138, Paris, France
[4] Univ Paris 05, UMRS 1138, Paris, France
[5] Lab Int Assoc INSERM, Paris, France
[6] ICMR, Paris, France
关键词
Haemophilia A; FVIII; Inhibitors; Autoantibodies; India; FACTOR-VIII INHIBITORS; PREVIOUSLY UNTREATED PATIENTS; RECOMBINANT FACTOR-VIII; RISK-FACTORS; ACQUIRED HEMOPHILIA; LUPUS ANTICOAGULANT; FACTOR-IX; HEPATITIS-C; EFFICACY; MARKERS;
D O I
10.1016/j.imlet.2015.09.013
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Diagnosis and management of haemophilia patients with inhibitors is often tricky due to the heterogeneous nature of the antibodies with regard to their kinetics, as well as the co-existence of other interfering antibodies. Plasma samples from severe haemophilia A patients from India with and without FVIII inhibitors were analysed for the presence of possible co-existing antibodies such as lupus anticoagulants (LA), anti-cardiolipin antibodies (ACLA), anti-132-glycoprotein-I (anti-beta 2-GP-I) antibodies, viral transfusion transmitted disease (HIV, HBsAg, HCV) related antibodies, anti-cyclic citrullinated peptides (anti-CCP), and anti-nuclear antibodies. A high incidence of LA and anti-HCV antibodies was detected in Indian haemophilia A patients similar to earlier reports. More importantly, a relatively high incidence of autoantibodies to nuclear antigens (18.62%) and anti-CCP antibodies (1.38%) associated with autoimmune disorders was also seen in these congenital haemophilia A patients with and without inhibitors. Knowledge on the antibody profile in these haemophilia patients especially in those with FVIII inhibitors along with correlation with the clinical manifestations and other risk factors for inhibitor development could possibly shed more light on the complex immune response in these patients. (C) 2015 Elsevier B.V. All rights reserved.
引用
收藏
页码:93 / 97
页数:5
相关论文
共 50 条
  • [21] On the way to low immunogenic FVIII-Preparations Development of Inhibitors in severe Haemophilia A
    Menke, Petra
    HAMOSTASEOLOGIE, 2014, 34 (04): : 327 - 329
  • [22] Analysis of F8 inversions as risk factors for FVIII inhibitor development in Indian severe haemophilia A patients
    Pinto, Patricia
    Ghosh, Kanjaksha
    Shetty, Shrimati
    BLOOD CELLS MOLECULES AND DISEASES, 2014, 53 (03) : 161 - 163
  • [23] SAFETY AND EFFICACY OF MARSTACIMAB FOR PREVENTION OF BLEEDING EPISODES IN PAEDIATRIC PATIENTS WITH SEVERE HAEMOPHILIA A OR MODERATELY SEVERE TO SEVERE HAEMOPHILIA B WITH OR WITHOUT INHIBITORS
    Teeter, J.
    Charnigo, R.
    Cossons, N.
    Raje, S.
    Hwang, E.
    Le Duigou, T.
    HAEMOPHILIA, 2022, 28 : 88 - 89
  • [24] FVIII inhibitors in haemophilia A patients who are considered as previously treated patients.
    von Auer, C
    Krause, M
    Miesbach, W
    Scharrer, I
    Asmelash, G
    Stier-Brueck, I
    BLOOD, 2004, 104 (11) : 91B - 92B
  • [26] FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors
    Hofbauer, Christoph J.
    Kepa, Sylvia
    Schemper, Michael
    Quehenberger, Peter
    Reitter-Pfoertner, Sylvia
    Mannhalter, Christine
    Reipert, Birgit M.
    Pabinger, Ingrid
    BLOOD, 2016, 128 (02) : 293 - 296
  • [27] Impact of FVIII product change in severe haemophilia A patients previously treated with plasma-derived FVIII
    Mingot, M. E.
    Heiniger, A., I
    Garcia, M.
    Fernandez, J. A.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1124 - 1124
  • [28] Surgery in haemophilia patients with inhibitors to FVIII/FIX: the Norwegian single centre study
    Holme, P. A.
    Tran, H. T. T.
    Paus, A.
    Tjonnfjord, G. E.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 512 - 512
  • [29] Emicizumab prophylaxis in patients with haemophilia A with and without inhibitors
    Ebbert, Patrick T.
    Xavier, Frederico
    Seaman, Craig D.
    Ragni, Margaret V.
    HAEMOPHILIA, 2020, 26 (01) : 41 - 46
  • [30] Cross-reacting recombinant porcine FVIII inhibitors in patients with acquired haemophilia A
    Bowyer, Annette
    Shepherd, Fiona
    Platton, Sean
    Guy, Susan
    Kitchen, Steve
    Maclean, Rhona
    HAEMOPHILIA, 2020, 26 (06) : 1181 - 1186